Витамин D и рак молочной железы у женщин


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Исследования последних лет обнаружили связь дефицита витамина D и широкого спектра заболеваний - сердечно-сосудистой патологии, депрессии, сахарного диабета, болезни Альцгеймера и ряда онкологических заболеваний. Многочисленные исследования показали прямую связь между низким уровнем витамина D и частотой рака молочной железы, риском отдаленных метастазов и общей выживаемостью. Установлена значимость не только абсолютной концентрации витамина D, но и регулирующее влияние рецепторов витамина D и основных ферментов, определяющих локальный метаболизм витамина D. Полиморфизм гена витамина D и различная экспрессия ферментов, участвующих в синтезе биологически активной формы витамина D и катаболизме витамина, в конечном итоге определяют локальную концентрацию витамина D. Последний, в свою очередь, регулирует пролиферацию клеток молочной железы, что является основой доброкачественных поражений и онкопатологии молочной железы. Это позволяет рассматривать коррекцию дефицита витамина D как один из эффективных методов первичной профилактики рака молочной железы.

Полный текст

Доступ закрыт

Об авторах

Лариса Ивановна Мальцева

ГБОУ ДПО Казанская государственная медицинская академия Минздрава России

Email: laramalc@mail.ru
д.м.н., профессор, зав. кафедрой акушерства и гинекологии № 1

Юлия Владимировна Гарифуллова

ГБОУ ДПО Казанская государственная медицинская академия Минздрава России

Email: gamgg@yandex.ru
аспирант кафедры акушерства и гинекологии № 1

Список литературы

  1. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press; 2010.
  2. Bischoff-Ferrari H.A., Burckhardt P., Quack-Loetscher K., Gerber B., I’Allemand D., Laimbacher J., Bachmann M., Rizzoli R. Vitamin D deficiency: evidence, safety, and recommendations for the Swiss population. Report written by a group of experts on behalf of the Federal Commission for Nutrition (FCN). 2012. Available at: http://www.iccidd.org/p142000804. html. 3.
  3. Dawson-Hughes B., Mithal A., Bonjour J.P., Boonen S., Burckhardt P., Fuleihan G.E. et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 2010; 21(7): 1151-4.
  4. Elamin M.B., Abu Elnour N.O., Elamin K.B., Fatourechi M.M., Alkatib A.A., Almandoz J.P. et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2011; 96 (7): 1931-42.
  5. Howland R.H. Vitamin D and depression. J. Psychosoc. Nurs. Ment. Health Serv. 2011; 49(2): 15-8.
  6. Lenders C.M., Feldman H.A., Von Scheven E., Merewood A., Sweeney C., Wilson D.M. et al. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am. J. Clin. Nutr. 2009; 90(3): 459-67.
  7. Littlejohns T.J., Henley W.E., Lang I.A., Annweiler C., Beauchet O., Chaves P.H. et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014; 83(10): 920-8.
  8. Mitri J., PittasA.G. Vitamin D and diabetes. Endocrinol. Metab. Clin. North Am. 2014; 43(1): 205-32.
  9. OoinL.L., Zhou H., KalaknnR., Zheng Y., ConigravenA.D., SeibelnM.J., Dunstan C.R. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 2010; 70(5): 1835-44.
  10. Garland C., Garland F., Gorham E. Epidemiology ofcancer risk and vitamin D. In: Holick M., ed. Vitamin D: molecular biology, physiology, and applications. Totowa, New Jersey: Humana Press; 1999: 375-409.
  11. John E.M., Schwartz G.G., Dreon D.M., Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol. Biomarkers Prev. 1999; 8(5): 399-406.
  12. Gorham E.D., Garland C.F, Garland F.C. Acid haze air pollution and breast and colon cancer in 20 Canadian cities. Can. J. Public Health. 1989; 80(2): 96-100.
  13. GarlandnF.C., Garland C.F, Gorham E.D., Young J.F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 1990; 19(6): 614-22.
  14. Garland C.F., Gorham E.D.,Mohr S.B., Grant W.B., Giovannucci E.L., Lipkin M. et al. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 2007; 103(3-5): 708-11.
  15. Rejnmark L., Tietze A., Vestergaard P., Buhl L., Lehbrink M., Heickendorff L., Mosekilde L. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2009; 18(10): 2655-60.
  16. Toner C.D., Davis C.D., John A. Milner J.A. The vitamin D and cancer conundrum: aiming at a moving target. J. Am. Diet. Assoc. 2010; 110(10): 1492-500.
  17. Goodwin P.J., Ennis M., Pritchard K.I., Koo J., Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol. 2009; 27(23): 3757-63.
  18. Colston K.W. Vitamin D and breast cancer risk. Best Pract. Res. Clin. Endocrinol. Metab. 2008; 22(4): 587-99.
  19. Zinser G.M., Suckow M., Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues, J. Steroid Biochem. Mol. Biol. 2005; 97(1-2): 153-64.
  20. McCullough M.L., Bostick R.M., Mayo T.L. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu. Rev. Nutr. 2009; 29: 111-32.
  21. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009; 30(7): 1170-80.
  22. Tang C., Chen N., Wu M., Yuan H., Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res. Treat. 2009; 117(2): 391-9.
  23. Colin E.M., Weel A.E., Uitterlinden A.G., Buurman C.J., Birkenhäger J.C., Pols H.A., van Leeuwen J.P. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. (Oxford). 2000; 52(2): 211-6.
  24. Uitterlinden A.G., Fang Y., Van Meurs J.B., Pols H.A., Van Leeuwen J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004; 338(2): 143-56.
  25. Mehta R.G., Peng X., Alimirah F., Murillo G., Mehta R. Vitamin D and breast cancer: emerging concepts. Cancer Lett. 2013; 334(1): 95-100.
  26. Dalessandri K.M., Miike R., Wiencke J.K., Farren G., Pugh T.W., Manjeshwar S. et al. Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study. J. Am. Coll. Surg. 2012; 215(5): 652-7.
  27. Lundin A.C., Soderkvist P., Eriksson B., Bergman-Jungestrom M., Wingren S. South-East Sweden Breast Cancer Group. Association of breast cancer progression with a vitamin D receptor gene polymorphism. Cancer Res. 1999; 59(10): 2332-4.
  28. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., Colston K.W. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotypes and breast cancer risk in a UK Caucasian population. Eur. J. Cancer. 2005; 41(8): 1164-9.
  29. Lopes N., Sousa B., Martins D., Gomes M., Vieira D., Veronese L.A. et al. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.BMC Cancer. 2010, 10: 483. Available at: http://www.biomedcentral.com/1471-2407/10/483
  30. Fillenberg S., Johanna L., Loreen R., Schmidmayr M., Artmann A., Kiechle M., Seifert-Klauss V. Vitamin D and breast density in pre- and postmenopausal women. In: 9th European Congress on Menopause and Andropause. Athens Greece, 28-31 March, 2012. Maturitas. 2012; 71(Suppl.1): S1-82.
  31. Sprague B.L., Trentham-Dietz A., Gangnon R.E., Buist D.S., Burnside E.S., Aiello Bowles E.J. et al. The vitamin D pathway and mammographic breast density among postmenopausal women. Breast Cancer Res. Treat. 2012; 131(1): 255-65. doi: 10.1007/s10549-011-1726-5.
  32. Bérubé S., Diorio C., Mâsse B., Hébert-Croteau N., Byrne C., Côté G. et al. Vitamin D and calcium intakes from food or supplements and mammo-graphic breast density. Cancer Epidemiol. Biomarkers Prev. 2005; 14(7): 1653-9.
  33. Simpson E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 2003; 86(3-5): 225-30.
  34. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm. IGF Res. 2003; 13(4): 113-70.
  35. Swami S., Krishnan A.V., Feldman D. 1alpha, 25-Dihydroxyvitamin D3 downregulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res. 2000; 6(8): 3371-9.
  36. Bouvard B., Annweiler C., Sallé A., Beauchet O., Chappard D., Audran M., Legrand E. Extraskeletal effects of vitamin D: Facts, uncertainties, and controversies Joint Bone Spine. 2011; 78(1): 10-6.
  37. Chlebowski R.T. Nutrition and physical activity influence on breast cancer incidence and outcome. The Breast. 2013; 22(Suppl.2): S30-7.
  38. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 2007; 85(6): 1586-91.
  39. Zeichner S.B., Koru-Sengul T., Shah N., Liu Q., Markward N.J., Montero A.J. et al. mproved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clin. Breast Cancer. 2015; 15(1): e1-11.
  40. Maalmi H., Ordönez-Mena J.M., Schöttker B., Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur. J. Cancer. 2014; 50(8): 1510-21.
  41. Buttigliero C., Monagheddu C., Petroni P., Saini A., Dogliotti L., Ciccone G., Berruti A. Prognostic role of vitamin D status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist. 2011; 16(9): 1215-27.
  42. Piura E., Chapman J.W, Lipton A., Zhu L., Leitzel K., Wilson C.F. et al. Serum 1-OH vitamin D and prognosis of postmenopausal breast cancer patients: NCIC-CTG MA 14 trial. J. Clin. Oncol. 2009; 27(Suppl.): A-534, 15s.
  43. Hansen C.M., Frandsen T.L., Brunner N., Binderup L. 1 alpha,25-dihy-droxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin. Exp. Metastasis. 1994; 12(3): 195-202.
  44. Sundaram S., Beckman M.J., Bajwa A., Wei J., Smith K.M., Posner G.H., Gewirtz D.A. QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol. Cancer Ther. 2006; 5(11): 2806-14.
  45. El Abdaimi K., Dion N., Papavasiliou V., Cardinal P.E., Binderup L., Goltzman D. et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000; 60(16): 4412-8.
  46. Yamamoto N., Suyama H., Yamamoto N., Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int. J. Cancer. 2008; 122(2): 461-7.
  47. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T., Hiragun A. Inhibition of angiogenesis by vitamin D3 analogues. Eur. J. Pharmacol. 1990; 178(2): 247-50.
  48. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 2000; 87(3): 214-20.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2015